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Sir,
In their recent British Journal of Cancer paper, Parker et al
(2006) were careful not to overplay the conclusions that can be
drawn from their model of the natural history of screen-detected
prostate cancer. They alerted the reader to the dangers of trying to
learn about the effects of treatment on localised prostate cancer
detected through prostate-specific antigen (PSA) testing when the
results of randomised controlled trials are not available and data
from observational studies are only available on men whose
cancers were detected at a later stage of the disease. Parker et al
also emphasised the importance of ongoing randomised trials,
such as ProtecT (Donovan et al, 2003), which will provide direct
and robust evidence of the effectiveness of different treatment
approaches in men with PSA-detected disease. Regrettably, these
notes of caution were absent from the ensuing coverage of the
study in the UK media (Press Association, 2006).
In the large majority of cases detected with PSA testing, prostate
cancer progresses very slowly, with death due to other causes most
commonly intervening before the disease becomes life-threatening
(Albertsen et al, 2005). PSA testing allows prostate cancer to be
detected earlier, before symptoms develop, but there has been
insufficient time since the introduction of testing in the 1990s for
the most beneficial treatment approaches to be established through
empirical studies. In this absence of observed data on the effects of
treatment on PSA-detected disease, Parker et al (2006) utilised
data on the 15-year survival of patients diagnosed at a later
stage of their disease and managed conservatively (Albertsen
et al, 1998), and data on the effect of radical vs conservative
treatment on survival in men detected clinically (Bill-Axelson
et al, 2005). These data informed a model that was used to
predict the 15-year survival and effects of conservative and
radical treatments in PSA-detected localised prostate cancer.
Looking at survival and treatment effects in subgroups of men
defined by their Gleason grade at diagnosis, Parker et al predicted
that only 1% of those with lower grade (Gleason score less than 7)
cancer would die of prostate cancer within 15 years, and concluded
that there is no scope for these men to benefit from radical
treatment.
A key feature of Parker et al’s (2006) model was the adjustment
for the ‘lead time’ that PSA testing provides, that is, the amount of
time by which PSA testing brings the diagnosis of prostate cancer
forward, hence allowing the disease to be treated in its early stages.
However, the estimated lead times may be too large, as they are
based on all men in a cohort with localised prostate cancer
irrespective of Gleason grade (Draisma et al, 2003). A proportion
of the 13-year lead time observed in that cohort will be due to
some cancers being diagnosed earlier and at a lower grade
with PSA testing (Draisma et al, in press). Parker et al’s (2006)
model incorporates Gleason grade at diagnosis, and so will capture
that part of the effect of screening and, equivalently, lead time
as more men diagnosed with lower grade cancer and so subject to
the lower 15-year mortality rate observed for men of that
cancer grade (Albertsen et al, 1998). Parker et al (2006) appear
not to take this part-accommodation of lead time into account,
using the full 13-year estimate from Draisma et al’s study (2003) to
calculate category-specific lead times for men with different
cancer grades at diagnosis. This ‘double-counting’ gives, for
example, an estimated lead time of 14.1 years in men aged 55–59
years with lower grade cancer, with the model consequently
only allowing death due to prostate cancer in the final 0.9 years of
the 15-year observation period. This reduces the 15-year mortality
from prostate cancer in that group of men from the 12%
observed in the early study of conservative treatment (Albertsen
et al, 1998) to a predicted 1% for contemporary cohorts with PSA-
detected disease.
All models are simplifications of reality, but may still be useful
despite their imperfections in the absence of trial evidence. It is
this very lack of evidence, together with other less formal
consideration of observational studies of conservative treatment
strategies (e.g. Chodak et al, 1994), that convinced the ProtecT
researchers to compare the effectiveness of active monitoring (i.e.
no immediate intervention, with PSA monitoring that can trigger
other treatments if the disease appears to be progressing) to that of
established radical treatments, that is, prostatectomy and radio-
therapy. Earlier observational studies created enough doubt in our
current knowledge of the relative risk-benefit of immediate radical
treatment for the ProtecT researchers to initiate a trial comparing
conservative and radical approaches to treatment. This is in
contrast to the press coverage resulting from Parker et al’s (2006)
study that implied similar data established the relative benefits to
be gained from the different treatments, without the need for
randomised controlled trials. In particular, they question the
suitability of the large majority of men with Gleason scores of less
than 7 for radical treatment.
The ProtecT trial (comparing radical surgery, radical conformal
radiotherapy and active monitoring) is still open to recruitment in
the UK, as is Parker et al’s study of ‘active surveillance’ (Parker,
2004; Hardie et al, 2005). Men who read the press reports arising Published online 26 September 2006
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the strength of available evidence, and may wrongly assume that
taking part in the ProtecT trial is unnecessary or even
inappropriate. It remains the case that it is only through the
conduct of a randomised study such as the ProtecT trial that we
will be able to provide robust and directly relevant data to inform
the management of contemporary cohorts of men with PSA-
detected localised prostate cancer.
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